Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A2A receptor antagonists

被引：0
|
作者：
Shah, U
Boyle, CD
Chackalamannil, S
Neustadt, B
Foster, C
Arik, L
Zhai, Y
Lachowicz, JE
Ng, K
Shiyong, W
Monopoli, A
Ongini, E
机构：
[1] Schering Plough Corp, CNS CV Chem Res, Kenilworth, NJ 07033 USA
[2] Schering Plough Corp, CNS Dept Biol Res, Kenilworth, NJ 07033 USA
[3] Schering Plough Corp, Drug Metab & Pharmacokinet, Kenilworth, NJ 07033 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2005年 / 230卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
MEDI-76
引用
收藏
页码：U2549 / U2550
页数：2
相关论文
共 50 条
  • [31] Discovery and characterization of novel highly potent A2A adenosine receptor antagonists for cancerimmunotherapy
    Lee, Kyungik
    Jun, Seungah
    Byun, EunYoung
    Lee, Hosun
    Lee, Yongtaek
    Moon, MiJin
    Kim, Yu-Yon
    Kang, Hyun Jeong
    Ahn, YoungGil
    Kim, YoungHoon
    Suh, Kwee Hyun
    CANCER RESEARCH, 2019, 79 (13)
  • [32] (-)-Mefloquine as a starting point for the discovery of selective adenosine A2A receptor antagonists
    Jordan, AM
    Benwell, K
    Cliffe, IA
    Dourish, CT
    Giles, PR
    Gillespie, RJ
    Knights, TR
    Lerpiniere, L
    Misra, A
    Ward, SE
    Weiss, SM
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2550 - U2551
  • [33] OPTIMIZATION OF NOVEL HETEROARYL DERIVATIVES AS POTENT AND SELECTIVE ADENOSINE A3 RECEPTOR ANTAGONISTS: IN VITRO PHARMACOLOGICAL AND ADME-PK PROFILE
    Celanire, Sylvain
    Bolea, Christelle
    Lambeng, Nathalie
    Poli, Sonia
    Poirier, Nicolas
    Fonteny, Fabien
    Lasserre, Sandrine
    Rencurosi, Anna
    Farina, Marco
    Parini, Carlo
    Mortoni, Annalisa
    Gagliardi, Stefania
    Rocher, Jean-Philippe
    Le Poul, Emmanuel
    DRUGS OF THE FUTURE, 2009, 34 : 94 - 94
  • [34] Novel purine derivatives as selective adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
    Bamford, SJ
    Lerpiniere, J
    Stratton, GC
    Dawson, CE
    Pratt, RM
    Gaur, S
    Weiss, SM
    Knight, TR
    Misra, A
    Jones, J
    Benwell, K
    Upton, R
    Dourish, CT
    Cliffe, IA
    Gillespie, RJ
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 227 : U51 - U52
  • [35] Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats
    Monopoli, A
    Lozza, G
    Forlani, A
    Mattavelli, A
    Ongini, E
    NEUROREPORT, 1998, 9 (17) : 3955 - 3959
  • [36] Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice
    Domenici, M. R.
    Scattoni, M. L.
    Martire, A.
    Lastoria, G.
    Potenza, R. L.
    Borioni, A.
    Venerosi, A.
    Calamandrei, G.
    Popoli, P.
    NEUROBIOLOGY OF DISEASE, 2007, 28 (02) : 197 - 205
  • [37] SCH 58261 (an adenosine A2A receptor antagonist) reduces, only at low doses, K+-evoked glutamate release in the striatum
    Pintor, A
    Quarta, D
    Pèzzola, A
    Reggio, R
    Popoli, P
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 421 (03) : 177 - 180
  • [38] Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists
    Yang, Zhaohui
    Li, Xuan
    Ma, Haikuo
    Zheng, Jiyue
    Zhen, Xuechu
    Zhang, Xiaohu
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (01) : 152 - 155
  • [39] A2A Adenosine Receptor Antagonists in Neurodegenerative Diseases
    Merighi, Stefania
    Borea, Pier A.
    Varani, Katia
    Vincenzi, Fabrizio
    Jacobson, Kenneth A.
    Gessi, Stefania
    CURRENT MEDICINAL CHEMISTRY, 2022, 29 (24) : 4138 - 4151
  • [40] An efficient route to xanthine based A2A adenosine receptor antagonists and functional derivatives
    LaBeaume, Paul
    Dong, Ma
    Sitkovsky, Michail
    Jones, Elizabeth V.
    Thomas, Rhiannon
    Sadler, Sara
    Kallmerten, Amy E.
    Jones, Graham B.
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2010, 8 (18) : 4155 - 4157
12345